How long the patients should be on Plavix with DES?
药物支架病人应该服用氯吡格雷多长时间？
As a result, Plavix may be less effective in altering platelet activity in those people.
因此，波立维可能并不能有效的改变这些人的血小板活性。
They should talk with their health care professional if they have any concerns about Plavix.
当他们对波立维有任何疑虑时应该与其专业医护人员交谈。
The firms had expected to squeeze out billions more dollars, since their patent on Plavix lasts until 2012.
两个公司本打算从中再捞个几十亿，因为他们的专利权到2012年才截止。
Plavix does not have its anti-platelet effects until it is metabolized into its active form by the liver enzyme, CYP2C19.
波立维在被肝酶cyp2c 19代谢转化为其活性形式前不具有抗血小板作用。
Antiplatelet drugs, such as Plavix, are used to help prevent potentially dangerous blood clots from forming in people with heart disease.
抗血小板药物(例如波利维)被用来帮助预防伴心脏病人群中潜在有危险性的血栓形成。
Perhaps, according to a study that found the risk of heart attack or death jumped when patients went off the popular blood thinner Plavix.
有可能，根据一项研究发现：当患者停用了常用抗血小板药物波立维后，心脏突发事件或死亡率会突然增长。
Conclusions Interindividual variability in the platelet inhibitory response from plavix occurs in patients undergoing elective coronary stenting.
结论：在行选择性冠状动脉支架植入术的病人对波力维产生的血小板抑制反应存在个体差别。
Objective To investigate individual variations of platelet inhibition after Plavix being administered to prevent clinic events and stent thrombosis.
目的：研究预防支架术后临床事件和血栓形成服用波力维后，血小板抑制的个体差别。
These "poor metabolizers" may not receive the full benefit of Plavix treatment and may remain at risk for heart attack, stroke, and cardiovascular death.
这些“代谢功能不全者”可能不能够获得波立维的全部疗效并可能继续承担心脏病发作，脑卒中，和心血管死亡的风险。
Further research showed using PPIs along with Plavix did not lead to any significant increase in the risk of heart disease events like heart attack or stroke.
进一步的研究显示质子泵抑制剂与波利维一起没有导致像心肌梗塞或中风等心脏病事件风险的显著增加。
Plavix reduces the risk of heart attack, unstable angina, stroke, and cardiovascular death in patients with cardiovascular disease by making platelets less likely to form blood clots.
波立维通过不使血小板造成凝血而降低心脏病发作，不稳定心绞痛，脑卒中，和心血管疾病患者的心血管死亡的风险。
The FDA staff also notes that patients who received prasugrel were more likely to develop cancer than those who took Plavix, though it's not clear whether prasugrel actually raises the risk of cancer.
同时FDA文件提到接受普拉格雷治疗的患者相对接受氯比格雷治疗的患者更容易患上癌症，虽然目前不清楚是否由于使用了普拉格雷而导致癌症的产生。
The FDA staff also notes that patients who received prasugrel were more likely to develop cancer than those who took Plavix, though it's not clear whether prasugrel actually raises the risk of cancer.
同时FDA文件提到接受普拉格雷治疗的患者相对接受氯比格雷治疗的患者更容易患上癌症，虽然目前不清楚是否由于使用了普拉格雷而导致癌症的产生。
应用推荐